| Pharmaceutical Information |
| Drug Name |
Fludarabine |
| Drug ID |
BADD_D00914 |
| Description |
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. |
| Indications and Usage |
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen |
| Marketing Status |
approved |
| ATC Code |
L01BB05 |
| DrugBank ID |
DB01073
|
| KEGG ID |
D07966
|
| MeSH ID |
C024352
|
| PubChem ID |
657237
|
| TTD Drug ID |
D0F2XQ
|
| NDC Product Code |
16729-131 |
| UNII |
P2K93U8740
|
| Synonyms |
fludarabine | 9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- | F-ara-A | 2-fluoroadenine arabinoside | 9-beta-D-arabinofuranosyl-2-fluoroadenine |
|
| Chemical Information |
| Molecular Formula |
C10H12FN5O4 |
| CAS Registry Number |
21679-14-1 |
| SMILES |
C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
